KRAS NP_004976.2:p.G12C
Bristol Myers Squibb Completes $4.8 Billion Acquisition of Mirati Therapeutics
Bristol Myers Squibb; Mirati Therapeutics; acquisition; $4.8 billion; KRAZATI; oncology; KRAS G12C
Actionable Insights Powered by AI
Bristol Myers Squibb; Mirati Therapeutics; acquisition; $4.8 billion; KRAZATI; oncology; KRAS G12C